Combining our time-tested abilities in developed and emerging international markets

The Causeway International Opportunities strategy is a blend of Causeway’s best skills, combining our international value (bottom-up, fundamental, developed international markets, excluding the US) and emerging markets (quantitatively managed with a targeted tracking error of 5%) equity strategies. Tracking error is a measurement of dispersion from a benchmark index. Our quantitative research team developed a proprietary multi-factor model that measures the relative attractiveness of emerging markets, and guides the portfolio managers in tactically allocating between the developed and emerging portfolio segments.

Benchmark
MSCI ACWI ex US
Inception
June 30, 2007
Download Profile Sheet Download Flash Report Download Quarterly Review Risk Disclosures
Contact Us

Strategy overview

The portfolio managers discuss our International Opportunities strategy.

Portfolio managers

Fundamental Portfolio Manager
Fundamental Portfolio Manager
Quantitative Portfolio Manager
President
Head of Fundamental Research
Fundamental Portfolio Manager
Head of Quantitative Research
Quantitative Portfolio Manager
Chief Executive Officer
Fundamental Portfolio Manager
Quantitative Portfolio Manager
Fundamental Portfolio Manager
Fundamental Portfolio Manager
Quantitative Portfolio Manager
Fundamental Portfolio Manager
Fundamental Portfolio Manager

Performance

Table Header QTD YTD 1 year3 years5 years Since inception
Strategy (gross) 2.5%31.7%30.9%21.9%12.8%9.5%6.1%
Strategy (net) 2.4%31.2%30.4%21.3%12.3%9.1%5.8%
MSCI ACWI ex US 2.0%29.2%26.7%16.5%9.0%8.4%4.4%
Table Header QTD YTD 1 year3 years5 years Since inception
Strategy (gross) 2.5%31.7%30.9%21.9%12.8%9.5%6.1%
Strategy (net) 2.4%31.2%30.4%21.3%12.3%9.1%5.8%
MSCI ACWI ex US 2.0%29.2%26.7%16.5%9.0%8.4%4.4%
Table Header QTD YTD 1 year3 years5 years Since inception
Strategy (gross) 6.8%28.6%20.0%27.6%16.0%9.8%6.1%
Strategy (net) 6.7%28.1%19.5%27.0%15.5%9.3%5.7%
MSCI ACWI ex US 7.0%26.6%17.1%21.3%10.8%8.8%4.4%
Table Header QTD YTD 1 year3 years5 years Since inception
Strategy (gross) 6.8%28.6%20.0%27.6%16.0%9.8%6.1%
Strategy (net) 6.7%28.1%19.5%27.0%15.5%9.3%5.7%
MSCI ACWI ex US 7.0%26.6%17.1%21.3%10.8%8.8%4.4%
Fund 2024202320222021202020192018201720162015201420132012201120102009
Strategy (gross) 10.0%24.8%-11.1%8.0%6.5%23.4%-17.9%31.8%1.9%-4.0%-3.9%22.2%26.0%-11.7%15.5%48.8%
Strategy (net) 9.5%24.3%-11.4%7.6%6.1%22.9%-18.2%31.3%1.5%-4.4%-4.2%21.7%25.5%-12.0%15.1%48.4%
MSCI ACWI ex US 6.1%16.2%-15.6%8.3%11.1%22.1%-13.8%27.8%5.0%-5.3%-3.4%15.8%17.4%-13.3%11.6%42.1%
Table Header
Strategy (gross)
Strategy (net)
MSCI ACWI ex US
2024202320222021202020192018201720162015201420132012201120102009
10.0%24.8%-11.1%8.0%6.5%23.4%-17.9%31.8%1.9%-4.0%-3.9%22.2%26.0%-11.7%15.5%48.8%
9.5%24.3%-11.4%7.6%6.1%22.9%-18.2%31.3%1.5%-4.4%-4.2%21.7%25.5%-12.0%15.1%48.4%
6.1%16.2%-15.6%8.3%11.1%22.1%-13.8%27.8%5.0%-5.3%-3.4%15.8%17.4%-13.3%11.6%42.1%

Portfolio (as of November 30, 2025)

Benchmark: MSCI ACWI ex US
Asset Allocation
Table Header Strategy
Stocks 98.8%
Cash 1.2%
Strategy Characteristics
Table Header Strategy Benchmark
No. of holdings 232 1973
Weighted avg. market cap (US $MM) $116,027 $122,641
FY2 price/earnings 11.8 14.5
Price/book value 1.7 2.2
Dividend yield (%) 2.8 2.6
TOP 10 HOLDINGS
Security Country Percent
Kering SA France 3.9
Taiwan Semiconductor Manufacturing Co., Ltd. Taiwan 2.9
AstraZeneca PLC United Kingdom 2.7
Alstom SA France 2.5
Barclays PLC United Kingdom 2.3
Roche Holding AG Switzerland 2.3
Reckitt Benckiser Group Plc United Kingdom 2.3
Tencent Holdings Ltd. China 2.2
Renesas Electronics Corp. Japan 2.2
BNP Paribas SA France 1.8

A “weighted average” measures a characteristic by the market capitalization of each stock. Price/book ratio is the weighted average of the price/book ratios of all the stocks in a portfolio. The P/B ratio of a company is calculated by dividing the market price of its stock by the company’s per-share book value. The price/earnings ratio is the weighted average of the price/earnings ratios of the stocks in a portfolio. The FY2 P/E ratio is a forward P/E ratio using a next-twenty-four months EPS estimate in the denominator.

Holdings are subject to change.

SECTOR WEIGHTS
Sector Strategy Benchmark
Financials 18.7% 24.9%
Information Technology 16.9% 14.3%
Industrials 13.2% 14.6%
Consumer Discretionary 11.3% 10.1%
Health Care 10.7% 8.1%
Consumer Staples 7.4% 6.2%
Materials 7.0% 6.7%
Communication Services 6.3% 5.8%
Utilities 2.6% 3.2%
Energy 2.1% 4.5%
Real Estate 1.5% 1.6%
Equity Funds 1.1% 0.0%
TOP 10 COUNTRIES
Country Strategy Benchmark
United Kingdom 20.2% 9.0%
France 14.4% 6.6%
China 10.2% 8.8%
Japan 7.1% 13.8%
Taiwan 6.7% 6.1%
Germany 6.4% 5.8%
South Korea 5.3% 3.7%
Netherlands 4.8% 3.0%
India 4.8% 4.8%
United States 2.5% 0.0%
Regional Allocation
  • Euro 29.2%
  • Emerging Asia 27.6%
  • Europe - Other 25.0%
  • Pacific 7.8%
  • North America 4.2%
  • Emerging Europe, Middle East, Africa 2.2%
  • Emerging Latin America 1.8%
  • Multi Region 1.1%

Commentary (As of November 30, 2025)

Highlights

  • Global equity markets were broadly flat for November, but style performance diverged, with value stocks outperforming growth in certain regions.
  • US tariff negotiations with China are ongoing and the situation is complex – the average effective tariff rate far exceeds the reciprocal tariff rate due to various other tariffs on specific goods. We are overweight Chinese stocks in the Portfolio due in part to compelling valuation and growth characteristics.
  • In the developed markets portion of the portfolio, we are investing in companies with, in our view, durable pricing power, strong brands, and resilient product pipelines, and we view periods of temporary underperformance as opportunities to build positions at compelling valuations. We aim to hold management teams accountable for accelerating operational restructuring and improving shareholder returns. We remain confident that active management and disciplined stock selection should continue to uncover attractive opportunities across global markets.

Portfolio Attribution

The Portfolio outperformed the Index during the month, due primarily to stock selection. Portfolio holdings in the capital goods and banks industry groups, as well as an overweight position in the pharmaceuticals & biotechnology industry group, contributed to relative performance. Holdings in the materials, consumer durables & apparel, and consumer services industry groups offset some of the outperformance compared to the Index. The top contributor to return was pharmaceuticals & biotechnology company, Roche Holding AG (Switzerland). Other notable contributors included pharmaceutical company, AstraZeneca PLC (United Kingdom), and banking & financial services company, BNP Paribas SA (France). The largest detractor was integrated circuit manufacturer, Taiwan Semiconductor Manufacturing Co., Ltd. (Taiwan). Additional notable detractors included multinational luxury conglomerate, Kering SA (France), and cruise ship operator, Carnival Corp. (United States).

Investment Outlook

Market trends in 2025 year-to-date point to a notable shift in investor sentiment and capital rotation toward non-US equity markets. European fund inflows accelerated in the first half of the year, helping fuel the 12% appreciation of the euro versus the US dollar through the end of November. Year-to-date, US dollar weakness accounts for much of the outperformance of international markets. This strong developed international equity outperformance in US-dollar terms has likely renewed investor interest in undervalued European, UK, and Japanese equities. The current rise of international value indices over growth provides a constructive backdrop for our value-oriented investment style. Among the leading non-US sectors in 2025, we see continued upside potential in financials, industrials, information technology, and consumer staples. Several of the portfolio’s lagging stocks this year appear well-positioned to outperform in 2026 as management teams execute on earnings and cash-flow improvements, inspiring market confidence. In the developed markets portion of the portfolio, we are investing in companies with, in our view, durable pricing power, strong brands, and resilient product pipelines, and we view periods of temporary underperformance as opportunities to build positions at compelling valuations. We aim to hold management teams accountable for accelerating operational restructuring and improving shareholder returns. We remain confident that active management and disciplined stock selection should continue to uncover attractive opportunities across global markets.

In emerging markets, the tariff outlook for EM exports has generally improved, which has also bolstered EM assets. Reciprocal tariff rates in South Korea and Taiwan have been reduced and many goods, notably semiconductors, are excluded from the reciprocal tariffs currently. US tariff negotiations with China are ongoing and the situation is complex – the average effective tariff rate far exceeds the reciprocal tariff rate due to various other tariffs on specific goods. We are overweight Chinese stocks in the Portfolio due in part to compelling valuation and growth characteristics. In South Korea, corporate governance continues to improve. The Korean parliament passed an amendment to the Korean Commercial Act, which expands companies’ boards of directors’ fiduciary duties to also consider the interests of minority shareholders. We are overweight South Korean stocks in the Portfolio due in part to favorable valuation, growth, price momentum, and top-down characteristics.

The market commentary expresses the portfolio managers’ views as of the date of this report and should not be relied on as research or investment advice regarding any stock. These views and the portfolio holdings and characteristics are subject to change. There is no guarantee that any forecasts made will come to pass. The securities identified and described above do not represent all of the securities purchased, sold or recommended for client accounts. The reader should not assume that an investment in the securities identified was or will be profitable. Past performance does not guarantee future results. For a description of our performance attribution methodology, or to obtain a list showing every holding's contribution to the overall account's performance during the quarter, please contact our product manager, Kevin Moutes, at 310-231-6116 or [email protected].